

1 Title: Durability of antibody responses and frequency of clinical and subclinical SARS-CoV-2
2 infection six months after BNT162b2 COVID-19 vaccination in healthcare workers

3

4 Running title: Antibody durability post-BNT162b2

5

6 Eric D. Laing¹, Carol D. Weiss², Emily C. Samuels^{1,3}, Si'Ana A. Coggins^{1,3}, Wei Wang²,

7 Richard Wang², Russell Vassell², Spencer L. Sterling^{1,3}, Marana A. Tso¹, Tonia Conner¹, Emilie

8 Goguet^{1,3}, Matthew Moser^{1,3}, Belinda M. Jackson-Thompson^{1,3}, Luca Illinik^{3,4}, Julian Davies^{3,4},

9 Orlando Ortega^{3,4}, Edward Parmelee^{1,3}, Monique Hollis-Perry⁴, Santina E. Maiolatesi^{3,4}, Gregory

10 Wang^{4,5}, Kathleen F. Ramsey^{4,5}, Anatalio E. Reyes^{4,5}, Yolanda Alcorta^{4,5}, Mimi A. Wong^{4,5},

11 Alyssa R. Lindrose^{1,3}, Christopher A. Duplessis⁴, David R. Tribble¹, Allison M.W. Malloy¹,

12 Timothy H. Burgess¹, Simon D. Pollett^{1,3}, Cara H. Olsen¹, Christopher C. Broder¹, and Edward

13 Mitre*¹

14

15 ¹Uniformed Services University, Bethesda, MD, USA

16 ²US Food and Drug Administration, Silver Spring, MD, USA

17 ³Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, MD, USA

18 ⁴Naval Medical Research Center, Silver Spring, MD

19 ⁵General Dynamics Information Technology, Falls Church, VA

20

21 *correspondence, Edward Mitre, ORCID: 0000-0001-7506-3266

22

23

24 **Abstract**

25 Antibodies against SARS-CoV-2 decay but persist six months post-vaccination, with
26 lower levels of neutralizing titers against Delta than wild-type. Only 2 of 227 vaccinated
27 healthcare workers experienced outpatient symptomatic breakthrough infections despite 59 of
28 227 exhibiting serological evidence of exposure to SARS-CoV-2 as defined by development of
29 anti-nucleocapsid protein antibodies.

30

31 **Introduction**

32 Neutralizing and binding antibodies appear to be associated with protection against
33 symptomatic SARS-CoV-2 infection and COVID-19 (1, 2). Early assessments of the Pfizer-
34 BioNTech BNT162b2 COVID-19 mRNA vaccine observed > 95% effectiveness against
35 predominantly Alpha infections (3), but the potential impact of waning, post-vaccine neutralizing
36 titers is an ongoing concern (4).

37 Apparent increases in vaccine-breakthrough infections may be due to waning antibody
38 titers, increases in exposure risk as social distancing and mask wearing behaviors have
39 decreased, and reduced vaccine effectiveness against the Delta variant. Since mid-2021, Delta
40 has become the dominant genotype in the U.S. (5) and may cause increased hospitalization rates
41 in unvaccinated individuals compared to other variants (6). Additionally, Delta has increased
42 transmissibility compared to Alpha (7).

43 Because of growing concerns of vaccine-breakthrough risk, there has been a recent focus
44 on vaccine boosting strategies in higher risk groups. However, uncertainty and debate remains
45 about the need for vaccine boosters in generally healthy adults, including healthcare workers,
46 because of limited post-vaccination immunological and clinical data (8).

47 Here, we report the binding antibodies (bAb) and neutralizing antibodies (nAb) as well as
48 clinically overt and asymptomatic breakthrough infections that have occurred one year into the
49 Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study (9).

50

51 **The Study**

52 Generally healthy, adult HCWs at the Walter Reed National Military Medical Center
53 (WRNMMC) who were seronegative for IgG antibodies to SARS-CoV-2 spike glycoprotein
54 (spike) and had no history of COVID-19 were enrolled and followed in the PASS study as
55 described in Jackson-Thompson *et al.* (9). Participants' serum samples were collected monthly,
56 diluted 1:400, and screened for immunoglobulin G (IgG) reactivity against SARS-CoV-2 spike
57 and nucleocapsid protein (NP) in multiplex microsphere-based immunoassays, as previously
58 described (See Supplement). Additionally, participants were asked to obtain nasopharyngeal
59 SARS-CoV-2 PCR testing at the WRNMMC COVID-19 testing center upon experiencing
60 symptoms consistent with SARS-CoV-2 infection.

61 Quantification of spike-specific IgG antibody levels in World Health Organization BAU
62 was achieved by diluting serum samples at 1:400 and 1:8000, testing in a multiplex
63 immunoassay composed of SARS-CoV-2 spike and NP coupled microspheres, and then
64 interpolating against an internal standard curve calibrated to the NCI FNL U.S. SARS-CoV-2
65 IgG national standard (See Supplement, eFigure 1). Serum samples were assessed for nAb
66 against SARS-CoV-2 WT and Delta as previously described using a well-characterized SARS-
67 CoV-2 lentiviral pseudovirus neutralization assay to measure the potency of therapeutic
68 antibodies against emerging variants (See Supplement). All data were log₁₀-transformed. bAb
69 were analyzed by Wilcoxon matched-pairs signed rank test and nAb by repeated measures

70 Friedman ANOVA with Dunn's multiple comparisons performed post-hoc using GraphPad

71 Prism v9.0.

72 Excluding individuals infected prior to January 31 of 2021, the study followed 227
73 participants fully vaccinated with BNT162b2 and 17 unvaccinated participants. Participants were
74 generally healthy, with a mean age of 41.7 years (range 20 - 69) and were predominantly female
75 (Table 1).

76 Seroconversion was observed in all participants one month following the second vaccine
77 dose (Figure 1A). We quantified IgG bAb against spike at one and six months after full
78 vaccination in the 187 vaccinated participants with serum samples at both time points. Anti-spike
79 IgG bAb decreased from a geometric mean (GM) of 1929 BAU/mL (95%CI: 1752-2124) at one
80 month post-vaccination to a GM of 442 BAU/mL (95%CI: 399-490) at six months post-
81 vaccination ($P < 0.001$). Similarly, we observed decay of nAb between the one and six month-
82 post vaccination time points. Peak SARS-CoV-2 WT nAb decreased from a geometric mean titer
83 (GMT) of 551 (95% CI: 455-669) to 98 GMT (95% CI: 78-124) six months after full
84 vaccination. The nAb GMTs were significantly higher against SARS-CoV-2 WT compared to
85 SARS-CoV-2 Delta at both time points after vaccination (Figure 1C). In comparison, nAb
86 against Delta decayed from 279 GMT (95% CI: 219-355) at peak to 38 GMT (95% CI: 31-48)
87 after six months. Quantitative IgG bAb in BAU/ml correlated with nAb titers ($r = 0.70$, $P <$
88 0.001), demonstrating comparable decay of IgG bAb and nAb titers (eFigure 2).

89 In addition to anti-spike IgG bAb, we also monitored for seroconversion to IgG bAb to
90 NP. Of vaccinated subjects, 26.0% (59/227) developed NP seroconversion between March and
91 August of 2021 (Figure 2). Only two had symptomatic, PCR-positive vaccine breakthrough
92 infections, both of which were self-limited, outpatient cases. In the unvaccinated cohort, four

93 participants were diagnosed with SARS-CoV-2 infection: two by PCR when experiencing
94 symptomatic infection (one outpatient case, one requiring inpatient ICU care) and two with
95 pauci-symptomatic infection (both diagnosed by spike IgG seroconversion who reported mild
96 symptoms retrospectively). The frequency of NP seroconversions in the vaccinated population
97 correlated with the frequency of SARS-CoV-2 infections diagnosed in the unvaccinated
98 participants, 23.5% (4/17) (Figure 2), suggesting similar exposure rates.

99

100 **Conclusions**

101 In this prospective cohort study of generally healthy adult HCWs, we find that SARS-
102 CoV-2 spike IgG bAb and nAb induced by BNT162b2 mRNA COVID-19 vaccination wane, but
103 persist through six months following vaccination, corroborating results of another study (10).
104 Consistent with another report (11), significantly lower vaccine-induced nAb titers were
105 observed against Delta compared to WT. Asymptomatic infections determined by NP
106 seroconversions were relatively frequent, but symptomatic infection was rare, and severe disease
107 was absent.

108 We observed one of 17 unvaccinated individuals develop severe COVID-19, versus no
109 severe cases in 227 vaccinated participants. Of vaccinated individuals, there were two
110 symptomatic, PCR-proven breakthrough infections, both of which were managed as outpatients.
111 Interestingly, we observed that 26% of vaccinated participants developed antibodies against
112 SARS-CoV-2 NP, suggesting that vaccinated subjects experienced exposures to SARS-CoV-2 as
113 frequently as the unvaccinated population, yet rarely developed overt clinical disease. These
114 results suggest that the BNT162b2 vaccine confers protection against severe clinical disease for

115 at least six months in generally healthy adults, even in the face of frequent exposures to the virus
116 and waning antibodies, though does not protect fully against mild disease.

117 The strengths of the study include the frequency of serological assessments and the use of
118 variant specific nAb in addition to multiplexed antigen-specific IgG detection. Use of
119 longitudinal serological assessments enabled detection of asymptomatic and/or pauci-
120 symptomatic SARS-CoV-2 exposures, in addition to PCR testing triggered when participants
121 exhibited symptoms. While we were powered to show clear differences in antibody titers over
122 time, the study limitations include the moderate size of the cohort. Further, NP has lower
123 sensitivity and specificity compared to spike protein, and is therefore a limited marker for
124 subclinical SARS-CoV-2 infection (12). Indeed, NP seroconversion reportedly occurred in only
125 71% of PCR-confirmed vaccine breakthrough infections and is correlated with COVID-19
126 severity (13).

127 We observed persistence of nAb titers against SARS-CoV-2 WT equal to or greater than
128 the lowest dilution tested in 90% (44/49) of healthy adults six months after vaccination with
129 BNT162b2. Neutralizing activity against Delta was lower, with only 47% (23/49) of participants
130 maintaining nAb titers above the lowest dilution at six months post-vaccination. The decrease in
131 nAb does not necessarily mean that individuals have lost protection against severe COVID-19, as
132 nAb titers required for protection are not known and neutralization is only one function of
133 antibodies. In addition, memory B cells and T cells have been detected 8-12 months after SARS-
134 CoV-2 infection, demonstrating that adaptive immune memory can be long-lasting to SARS-
135 CoV-2 (14, 15). Further research is needed to understand the correlates of protection against
136 moderate to severe COVID-19, and SARS-CoV-2 variants.

137

138 **Acknowledgements**

139 ***Funding***

140 This work was supported by awards from the Defense Health Program and the CARES Act
141 [HU00012020067] and the National Institute of Allergy and Infectious Disease
142 [HU00011920111]. The protocol was executed by the Infectious Disease Clinical Research
143 Program (IDCRP), a Department of Defense (DoD) program executed by the Uniformed
144 Services University of the Health Sciences (USUHS) through a cooperative agreement by the
145 Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. (HJF). This
146 project has been funded in part by the National Institute of Allergy and Infectious Diseases at the
147 National Institutes of Health, under an interagency agreement [Y1-AI-5072].

148 ***Disclaimer***

149 EDL, CDW, WW, RV, TC, KMH-P, CAD, AMWM, THB, CO, CCB, and EM are military
150 Service members or employees of the U.S. Government. This work was prepared as part of their
151 official duties. Title 17, U.S.C., §105 provides that copyright protection under this title is not
152 available for any work of the U.S. Government. Title 17, U.S.C., §101 defines a U.S.
153 Government work as a work prepared by a military Service member or employee of the U.S.
154 Government as part of that person's official duties. The views expressed in this article are those
155 of the authors and do not necessarily reflect the official policy or position of the Uniformed
156 Services University of the Health Sciences, Walter Reed National Military Medical Center,
157 Naval Medical Research Center, the Department of Navy, the Department of Defense, the Henry
158 M. Jackson Foundation for the Advancement of Military Medicine, the U.S. Food and Drug
159 Administration, or the U.S. Government. Mention of trade names, commercial products, or
160 organizations does not imply endorsement by the U.S. Government.

161 ***Potential Conflicts of Interest***

162 DRT, THB, SDP: The Uniformed Services University (USU) Infectious Diseases Clinical
163 Research Program (IDCRP), a U.S. Department of Defense institution, and the Henry M.
164 Jackson Foundation (HJF) were funded under a Cooperative Research and Development
165 Agreement to conduct an unrelated Phase III COVID-19 monoclonal antibody immune-
166 prophylaxis trial sponsored by AstraZeneca. The HJF, in support of the USU IDCRP, was
167 funded by the Department of Defense Joint Program Executive Office for Chemical, Biological,
168 Radiological and Nuclear Defense to augment the conduct of an unrelated Phase III vaccine trial
169 sponsored by AstraZeneca. Both these trials were part of the US Government COVID-19
170 response. Neither is related to the work presented here.

171 ***Ethics Approval***

172 This study protocol was approved by the Uniformed Services University of the Health Sciences
173 Institutional Review Board (FWA 00001628; DoD Assurance P60001) in compliance with all
174 applicable Federal regulations governing the protection of human participants. Written consent
175 was obtained from all study participants.

176

177

178

179

180

181

182

183

184 **References**

- 185 1. Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing
186 antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2
187 infection. *Nat Med*. 2021 Jul;27(7):1205-11.
- 188 2. Gilbert PB, Montefiori DC, McDermott A, Fong Y, Benkeser DC, Deng W, et al. Immune
189 Correlates Analysis of the mRNA-1273 COVID-19 Vaccine Efficacy Trial. *medRxiv*. 2021 Aug
190 15.
- 191 3. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and
192 Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. *N Engl J Med*. 2021
193 Jul 22;385(4):320-9.
- 194 4. Fowlkes A, Gaglani M, Groover K, Thiese MS, Tyner H, Ellingson K. Effectiveness of
195 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before
196 and During B.1.617.2 (Delta) Variant Predominance - Eight U.S. Locations, December 2020-
197 August 2021. *MMWR Morb Mortal Wkly Rep*. 2021 Aug 27;70(34):1167-9.
- 198 5. U.S. Centers for Disease Control and Prevention. COVID Data Tracker September 14, 2021
199 [cited September 15, 2021]; Available from: [https://covid.cdc.gov/covid-data-tracker/#variant-](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)
200 [proportions](https://covid.cdc.gov/covid-data-tracker/#variant-proportions)
- 201 6. Twohig KA, Nyberg T, Zaidi A, Thelwall S, Sinnathamby MA, Aliabadi S, et al. Hospital
202 admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared
203 with alpha (B.1.1.7) variants of concern: a cohort study. *Lancet Infect Dis*. 2021 Aug 27.
- 204 7. Bolze A, Cirulli ET, Luo S, White S, Wyman D, Rossi AD, et al. SARS-CoV-2 variant Delta
205 rapidly displaced variant Alpha in the United States and led to higher viral loads. *medRxiv*.
206 2021:2021.06.20.21259195.

- 207 8. Krause PR, Fleming TR, Peto R, Longini IM, Figueroa JP, Sterne JAC, et al. Considerations
208 in boosting COVID-19 vaccine immune responses. *The Lancet*.
- 209 9. Jackson-Thompson BM, Goguet E, Laing ED, Olsen CH, Pollett S, Hollis-Perry KM, et al.
210 Prospective Assessment of SARS-CoV-2 Seroconversion (PASS) study: an observational cohort
211 study of SARS-CoV-2 infection and vaccination in healthcare workers. *BMC Infect Dis*. 2021
212 Jun 9;21(1):544.
- 213 10. Thomas SJ, Moreira ED, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Six Month
214 Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *medRxiv*.
215 2021:2021.07.28.21261159.
- 216 11. Chia PY, Xiang Ong SW, Chiew CJ, Ang LW, Chavatte J-M, Mak T-M, et al. Virological
217 and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-
218 center cohort study. *medRxiv*. 2021:2021.07.28.21261295.
- 219 12. Laing ED, Sterling SL, Richard SA, Epsi NJ, Coggins S, Samuels EC, et al. Antigen-based
220 multiplex strategies to discriminate SARS-CoV-2 natural and vaccine induced immunity from
221 seasonal human coronavirus humoral responses. *medRxiv*. 2021 Feb 12.
- 222 13. Pollett SD, Richard SA, Fries AC, Simons MP, Mende K, Lalani T, et al. The SARS-CoV-2
223 mRNA vaccine breakthrough infection phenotype includes significant symptoms, live virus
224 shedding, and viral genetic diversity. *Clin Infect Dis*. 2021 Jun 12.
- 225 14. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to
226 SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021;371(6529):eabf4063.
- 227 15. Turner JS, Kim W, Kalaidina E, Goss CW, Rauseo AM, Schmitz AJ, et al. SARS-CoV-2
228 infection induces long-lived bone marrow plasma cells in humans. *Nature*. 2021
229 2021/07/01;595(7867):421-5.

230 Address for correspondence: Edward Mitre, Department of Microbiology and Immunology,
 231 Uniformed Services University, 4301 Jones Bridge Road, Bethesda, MD 20814; email:
 232 edward.mitre@usuhs.edu, tel: 301-295-1958

233

234 **Table 1. Participant demographics.**

	BNT162b2 vaccinated (n=227)	Vaccinated with six months follow-up bAb (n = 187)	Vaccinated with six months follow-up nAb titers (n = 49)	Unvaccinated (n=17)
Sex				
Female (%)	159 (70)	131 (70)	33 (67)	13 (76)
Male (%)	68 (30)	56 (30)	16 (33)	4 (24)
Ethnicity				
Non-Hispanic (%)	209 (92)	175 (94)	47 (96)	16 (94)
Hispanic (%)	14 (6)	10 (5)	1 (2)	1 (6)
Not Reported	4 (2)	2 (1)	1 (2)	0
Race				
White (%)	165 (73)	139 (74)	35 (71)	9 (53)
Black (%)	26 (11.5)	18 (9.5)	4 (8)	6 (35)
Asian (%)	23 (10)	19 (10)	8 (16)	1 (6)
Two or more (%)	7 (3)	6 (3)	1 (2)	1 (6)
Native Hawaiian or Other Pacific Islander (%)	1 (0.5)	1 (0.5)	1 (2)	0
Not reported (%)	5 (2)	4 (2)	0	0
Age, mean (range)	41.7 (20-69)	42.8 (21-69)	44.7 (26-69)	32.3 (19-50)

235

236

237

238

239

240

241 **Figure 1. Legend. Vaccine-induced binding and neutralizing antibody responses.**

242 (A) Kinetics of vaccine-induced spike IgG bAb preceding and following second vaccination,
243 participants n=227; MFI, median fluorescence intensity; shaded area indicates the
244 positive/negative anti-spike IgG threshold. (B) Spike IgG bAb (BAU/mL) were quantified from
245 serum samples collected one month (mean 36.9 days, range 23-81 days) and six months (mean
246 201.1 days, range 151-237 days) post vaccination, participants n=187; Wilcoxon matched-pairs
247 signed rank test **** $P < 0.001$, two-tailed; y-axis is log₂-scale (C) nAb titers against SARS-
248 CoV-2 wild-type (WT) and Delta (Δ) variant from serum samples collected one month (mean
249 30.8 days, range 28-42 days) and six months (mean 200.1 days, range 189-219 days) post
250 vaccination, participants n=49; Friedman ANOVA with Dunn's multiple comparisons performed
251 post-hoc *** $P < 0.001$, ** $P < .01$; y-axis is log₂-scale. All errors bars represent the geometric
252 mean and 95% confidence intervals.

253




254 **Figure 2. Legend. Timeline of antibody responses and SARS-CoV-2 infections in PASS**
255 **participants.**

256 Each horizontal bar represents the infection, vaccination, and serological status obtained on a
257 monthly basis of all PASS participants that had not been diagnosed with SARS-CoV-2 by PCR
258 or anti-spike (S) IgG seroconversion by January 31, 2021. White spaces indicate no data. Grey
259 bars represent negative anti-S IgG. Red bars indicate month of SARS-CoV-2 diagnosis by PCR
260 positivity or anti-S IgG seroconversion. Yellow bars indicate anti-S IgG seroconversion after
261 SARS-CoV-2 diagnosis in unvaccinated individuals, and orange bars indicate presence of both
262 anti-S and anti-NP antibodies in unvaccinated individuals. Light green bars indicate anti-S IgG
263 seroconversion after vaccination. Dark green bars indicate detection of anti-NP IgG antibodies in

264 addition to anti-S antibodies at timepoints post-vaccination. N = 17 unvaccinated and 227

265 vaccinated participants.

266

A.**B.****C.**

17 unvaccinated
 4 infections
 1 ICU admission
 1 outpatient symptomatic
 2 pauci-symptomatic

227 vaccinated
 59 anti-NP seroconversions
 2 outpatient symptomatic

- SARS-CoV-2 IgG seronegative
- COVID-19 diagnosis by PCR or seropositivity
- anti-S IgG positive after infection
- anti-S and anti-NP IgG positive after infection
- anti-S IgG positive after vaccination
- anti-S and anti-NP IgG positive after vaccination
- no data

